Q-omics provides the consensus-scored NKX2-6 profile across patient tissues and cancer cell-line models. NKX2-6 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, NKX2-6 is differentially expressed in 3, with the highest sampling consensus in HNSC. Additionally, NKX2-6 RNA expression shows 6,096 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KICH, HNSC, and STAD as cancer lineages where NKX2-6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NKX2-6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NKX2-6 survival associations across molecular data types. NKX2-6 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NKX2-6 RNA expression–survival associations across cancer types. High NKX2-6 expression shows unfavorable associations in KICH, LIHC, LUAD, ACC, READ and KIRC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for NKX2-6 RNA expression.
This table summarizes NKX2-6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NKX2-6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NKX2-6 shows lower tumor expression in HNSC and KICH and higher tumor expression in LUSC. The HNSC box plot shows higher NKX2-6 RNA expression in normal versus tumor tissue (log2 FC = −0.133, t-test p = .027).
This table shows molecular features associated with NKX2-6 in patient tissues and cancer cell lines. In patient samples, NKX2-6 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, NKX2-6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and LIVER.
